Progyny, Inc. (PGNY) stock
PGNYNasdaqServices-Misc Health & Allied Services, NECFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 21/303% below fair value
$36.58+0.08 (+0.22%)
Close on Nov 12, 2026Market cap $2.81BP/E 33.6Yield –
Progyny EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Progyny's EPS for the twelve months ending Sep 30, 2026 was $1.09, up 73.0% year over year. For fiscal 2025 it was $0.65, up 14.0% from the year before. The highest annual figure on record is $0.66 in fiscal 2021.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0.65 | +14.0% |
| FY2024 | Dec 31, 2024 | $0.57 | -8.1% |
| FY2023 | Dec 31, 2023 | $0.62 | +106.7% |
| FY2022 | Dec 31, 2022 | $0.30 | -54.5% |
| FY2021 | Dec 31, 2021 | $0.66 | +40.4% |
| FY2020 | Dec 31, 2020 | $0.47 | – |
| FY2019 | Dec 31, 2019 | -$0.41 | -1125.0% |
| FY2018 | Dec 31, 2018 | $0.04 | – |
| FY2017 | Dec 31, 2017 | -$2.37 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $0.32 | +113.3% |
| Q2 FY2026 | Jun 30, 2026 | $0.34 | +78.9% |
| Q1 FY2026 | Mar 31, 2026 | $0.29 | +70.6% |
| Q4 FY2025 | Dec 31, 2025 | $0.14 | +16.7% |
| Q3 FY2025 | Sep 30, 2025 | $0.15 | +36.4% |
| Q2 FY2025 | Jun 30, 2025 | $0.19 | +11.8% |
| Q1 FY2025 | Mar 31, 2025 | $0.17 | 0.0% |
| Q4 FY2024 | Dec 31, 2024 | $0.12 | -7.7% |
| Q3 FY2024 | Sep 30, 2024 | $0.11 | -31.3% |
| Q2 FY2024 | Jun 30, 2024 | $0.17 | +13.3% |
| Q1 FY2024 | Mar 31, 2024 | $0.17 | -5.6% |
| Q4 FY2023 | Dec 31, 2023 | $0.13 | +333.3% |
| Q3 FY2023 | Sep 30, 2023 | $0.16 | +23.1% |
| Q2 FY2023 | Jun 30, 2023 | $0.15 | +66.7% |
| Q1 FY2023 | Mar 31, 2023 | $0.18 | +260.0% |
| Q4 FY2022 | Dec 31, 2022 | $0.03 | -80.0% |
| Q3 FY2022 | Sep 30, 2022 | $0.13 | -23.5% |
| Q2 FY2022 | Jun 30, 2022 | $0.09 | -52.6% |
| Q1 FY2022 | Mar 31, 2022 | $0.05 | -66.7% |
| Q4 FY2021 | Dec 31, 2021 | $0.15 | -61.5% |
| Q3 FY2021 | Sep 30, 2021 | $0.17 | +240.0% |
| Q2 FY2021 | Jun 30, 2021 | $0.19 | – |
| Q1 FY2021 | Mar 31, 2021 | $0.15 | +275.0% |
| Q4 FY2020 | Dec 31, 2020 | $0.39 | – |
| Q3 FY2020 | Sep 30, 2020 | $0.05 | – |
| Q2 FY2020 | Jun 30, 2020 | -$0.01 | -200.0% |
| Q1 FY2020 | Mar 31, 2020 | $0.04 | – |
| Q4 FY2019 | Dec 31, 2019 | -$0.07 | – |
| Q3 FY2019 | Sep 30, 2019 | -$1.10 | – |
| Q1 FY2019 | Mar 31, 2019 | $0.01 | -98.6% |
| Q4 FY2018 | Dec 31, 2018 | -$0.30 | – |
| Q3 FY2018 | Sep 30, 2018 | -$0.20 | – |
| Q2 FY2018 | Jun 30, 2018 | -$0.22 | – |
| Q1 FY2018 | Mar 31, 2018 | $0.73 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?